| |
 GMF
V Introduction 
In a world of mobile capital and repetitive corporate
relocation, governments and regulators today struggle to attract, build
and maintain effective and profitable biomedical and healthcare clusters.
At the same time, corporations actively seek out those regulatory environments
in which they can maximize innovation and profitability and minimize conflict
with regulatory authorities. A balance is therefore sought by both parties,
whereby profitability is maintained, innovation stimulated and society
supported by the derivative excellent healthcare of a successful medical
sector.
GMF V, to take place in October 2007, will examine
this complex interplay from the many different perspectives of each of
the participants in the healthcare continuum in the search for applicable
solutions to current imbalances. Key questions and topics to be addressed
include:
On research. . .
- Is there a link between reference pricing and the relocation of research
capacity?
- Where will pharma and biotech innovation take place in the coming
two decades?
- Will India and China become new frontiers in medical research?
- How can societies regulate off-label drug use?
- Can the NIH model be transposed to other societies around the world?
- What is the long-term effect of current FDA policies and guidelines
on innovation in medicine?
- How does a regulatory body moniter drugs over the long term?
- Does the United States need a stricter medical technology evaluation
process?
- How can Europe create a better environment for research?
- How will personalized medicine affect regulatory constraints?
On coverage. . .
- How can a government protect solidarity during the transition to a
free market?
- How does over-regulation affect cost?
- What is the proper role of global institutions in healthcare development
in low-income countries?
- Case studies from the history of healthcare regulation: Successes
and failures
- The great Medicare experiment: Can public-private joint ventures succeed
in developed economies?
- How can a regulatory body support consumer driven healthcare?
On institutions....
- What is the prognosis for the state-owned university research hospital?
- Healthcare developments in the unregulated markets of the Middle East:
Pitfalls and successes
- How does a region build a medical cluster: Tax structures, real estate
laws, medical regulation
- Does the global press understand the complexity of healthcare and
regulation?
- Hospital development in China: The state of play
|
|
Site Links
 Executive Summary
GMF I Program
GMF II Program
GMF III Program
GMF IV Program
 GMF V Program
Contact the Foundation |
